# Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

> **NCT00538005** · PHASE1,PHASE2 · UNKNOWN · sponsor: **San Diego Pacific Oncology & Hematology Associates** · enrollment: 54 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** oxaliplatin
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00538005
- **Lead sponsor:** San Diego Pacific Oncology & Hematology Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** 2009-07
- **Final completion:** —
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538005, "Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00538005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*